Pharmacokinetic Study of mycophenolate mofetil combined with rituximab in patients with Childhood-onset Complicated Frequently Relapsing or Steroid-dependent Nephrotic Syndrome

Pharmacokinetic Study of mycophenolate mofetil combined with rituximab in patients with Childhood-onset Complicated Frequently Relapsing or Steroid-dependent Nephrotic Syndrome - Pharmacokinetic Study of MMF(JSKDC09)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016764

Enrollment

Registered

2015-03-10

Start date

2015-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood-onset Complicated Frequently Relapsing or Steroid-dependent Nephrotic Syndrome

Interventions

The measurement of the concentration of MPA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Subjects who enrolled in Mycophenolate mofetil for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind,randomised, placebo-controlled trial(JSKDC07) 2. Subjects have ability to provide written informed consent form. The written informed consent form of legal representative (i.e., a parent or a legal benefactor) is also required for subjects less than 20 years of age

Exclusion criteria

Exclusion criteria: 1. Judged inappropriate for this study by the physicians

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics parameters of MPA	—

Countries

Japan

Contacts

Public ContactMayumi Sako

National Center for Child Health and Development Division for Clinical Trials

sako-m@ncchd.go.jp03-3416-0181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026